HomeMore InformationMedical Literature
More Information

Literature

Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002; 115: 18-29

Barbeau WE. Interactions between dietary proteins and the human system: implications for oral tolerance and food-related diseases. Adv Exp Med Biol 1997; 415: 183-193

Bellmann K, Kolb H, Hartmann B, Rothe H, Rowsell P, Rastegar S, Burg-hardt K, Scott FW. Intervention in autoimmune diabetes by targeting the gut immune system. Int J Immu-nopharmacol 1997; 19: 573-577

Bindslev-Jensen C, Skov PS, Madsen F, Poulsen LK. Food allergy and food intolerance - what is the difference? Ann Allergy 1994; 72: 317-320

Borst SE, Bagby GJ. Neutralisation of tumour necrosis factor reverses age-induced impairment of insulin responsiveness in skeletal muscle of Sprague-Dawley rats. Metabolism 2002; 51: 1061-1064

Cavaillon JM. Cytokines in inflammation. C R Seances Biol Fil 1995; 189: 531-544

Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349-356

Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999; 1: S1-S7

Groux H, Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol Today 1999; 20: 442-446

Hanson SJ, Gause W, Natelson B. Detection of immunologically significant factors for chronic fatigue syndrome using neural-network classifiers. Clin Diagn Lab Immunol 2001; 8: 658-662

Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumour necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119

Lester MR, Hofer MF, Gately M, Trumble A, Leung DY. Down-regulating effects of IL-4 and IL-10 on the IFN-gamma response in atopic dermatitis. J Immunol 1995; 154: 6174-6181

Patton JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, Gavin LA, Grunfeld C. Interferons and tumour necrosis factors have similar catabolic effects on 3T3-L1 cells. Proc Natl Acad Sci USA 1986; 83: 8313-8317

Reaven GM. Role of insulin resistance in human disease. Diabetes1988; 37: 1595-1607

Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, Mac-Dermott RP, Raedler A. Enhanced secretion of tumour necrosis factor a, IL-6 and IL- 1b by isolated lamina propria mono-nuclear cells from patients with ulcerative Colitis and Crohn’s disease. Clin Exp Immunol 1993; 94: 174-181

Schafer ML. On the history of the concept neurasthenia and its modern variants chronic-fatigue-syndrome, fibromyalgia and multiple chemical sensitivities. Fortschr Neurol Psychiatry 2002; 70: 570-582

Secundolfo M, de Magistris L, Fiandra R, Caserta L, Bellatta M, Tartaglione MT, Riegler G, Biagi F, Corazza GR, Carratu R. Intestinal permeability in Crohn’s disease patients and their first degree relatives. Dig Liver Dis 2001; 33: 680-685

Targan SR. Biology of inflammation in Crohn’s disease: mechanisms of action of anti-TNF-a therapy. Can J Gastroenterol 2000; 14: S13-16

Tsuji NM, Mizumachi K, Kuriaski J. Interleukin-10-secreting Peyer’s patch cells are responsible for active suppression in low-dose oral tolerance. Immunology 2001; 4: 458-464

Vahasalo P, Petays T, Knip M, Miettinen A, Saukkonen T, Karjalainen J, Savilathi E, Ackerblom HK. Relation between antibodies to islet cell antigens, other auto antigens and cows milk proteins in diabetic children and unaffected siblings at the clinical manifestation of IDDM. The Childhood Diabetes in Finland Study Group. Autoimmunity 1996; 23: 165-174

White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population. Scand J Rheumatol 2000; 29: 44-51

Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumour necrosis factor-a concentrations in a native Canadian population with high rates of type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 272-278